Cytokine mediators of chronic graft-versus-host disease
Kelli P.A. MacDonald,1 Bruce R. Blazar,2 and Geoffrey R. Hill3,4
1Antigen Presentation and Immunoregulation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
2Masonic Cancer Center; and Division of Blood and Marrow Transplantation, Department of Pediatrics; University of Minnesota, Minneapolis, USA.
3Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
4Royal Brisbane and Women’s Hospital, Brisbane, Australia.
Address correspondence to: Kelli P.A. MacDonald, Antigen Presentation and Immunoregulation Laboratory, 300 Herston Road, Herston, Queensland 4006, Australia. Phone: 61.7.3362.0404; Email: kelli.macdonald@qimrberghofer.edu.au. Or to: Geoffrey R. Hill, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland 4006, Australia. Phone: 61.7.3845.3763; Email: Geoff.Hill@qimrberghofer.edu.au. Or to: Bruce R. Blazar, University of Minnesota, Department of Pediatrics, Division of Blood and Marrow Transplantation, MMC 109, 420 SE Delaware Street, Minneapolis, Minnesota 55455, USA. Phone: 612.626.1926; Email: blaza001@umn.edu.
Authorship note: B.R. Blazar and G.R. Hill contributed equally to this work.
Find articles by MacDonald, K. in: JCI | PubMed | Google Scholar
1Antigen Presentation and Immunoregulation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
2Masonic Cancer Center; and Division of Blood and Marrow Transplantation, Department of Pediatrics; University of Minnesota, Minneapolis, USA.
3Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
4Royal Brisbane and Women’s Hospital, Brisbane, Australia.
Address correspondence to: Kelli P.A. MacDonald, Antigen Presentation and Immunoregulation Laboratory, 300 Herston Road, Herston, Queensland 4006, Australia. Phone: 61.7.3362.0404; Email: kelli.macdonald@qimrberghofer.edu.au. Or to: Geoffrey R. Hill, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland 4006, Australia. Phone: 61.7.3845.3763; Email: Geoff.Hill@qimrberghofer.edu.au. Or to: Bruce R. Blazar, University of Minnesota, Department of Pediatrics, Division of Blood and Marrow Transplantation, MMC 109, 420 SE Delaware Street, Minneapolis, Minnesota 55455, USA. Phone: 612.626.1926; Email: blaza001@umn.edu.
Authorship note: B.R. Blazar and G.R. Hill contributed equally to this work.
Find articles by Blazar, B. in: JCI | PubMed | Google Scholar
1Antigen Presentation and Immunoregulation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
2Masonic Cancer Center; and Division of Blood and Marrow Transplantation, Department of Pediatrics; University of Minnesota, Minneapolis, USA.
3Bone Marrow Transplantation Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
4Royal Brisbane and Women’s Hospital, Brisbane, Australia.
Address correspondence to: Kelli P.A. MacDonald, Antigen Presentation and Immunoregulation Laboratory, 300 Herston Road, Herston, Queensland 4006, Australia. Phone: 61.7.3362.0404; Email: kelli.macdonald@qimrberghofer.edu.au. Or to: Geoffrey R. Hill, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Queensland 4006, Australia. Phone: 61.7.3845.3763; Email: Geoff.Hill@qimrberghofer.edu.au. Or to: Bruce R. Blazar, University of Minnesota, Department of Pediatrics, Division of Blood and Marrow Transplantation, MMC 109, 420 SE Delaware Street, Minneapolis, Minnesota 55455, USA. Phone: 612.626.1926; Email: blaza001@umn.edu.
Authorship note: B.R. Blazar and G.R. Hill contributed equally to this work.
Find articles by Hill, G. in: JCI | PubMed | Google Scholar
First published June 30, 2017 - More info
J Clin Invest. 2017;127(7):2452–2463. doi:10.1172/JCI90593.
Copyright © 2017, American Society for Clinical Investigation
Substantial preclinical and clinical research into chronic graft-versus-host disease (cGVHD) has come to fruition in the last five years, generating a clear understanding of a complex cytokine-driven cellular network. cGVHD is mediated by naive T cells differentiating within IL-17–secreting T cell and follicular Th cell paradigms to generate IL-21 and IL-17A, which drive pathogenic germinal center (GC) B cell reactions and monocyte-macrophage differentiation, respectively. cGVHD pathogenesis includes thymic damage, impaired antigen presentation, and a failure in IL-2–dependent Treg homeostasis. Pathogenic GC B cell and macrophage reactions culminate in antibody formation and TGF-β secretion, respectively, leading to fibrosis. This new understanding permits the design of rational cytokine and intracellular signaling pathway–targeted therapeutics, reviewed herein.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Print subscription
- $795
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2017 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)